Many companies are setting their strategy against a flawed view of the markets in which they compete. How sure are CEOs that their current growth strategy will achieve a competitive advantage and sustainable value over the next two to three years? In this article, we look at how to understand a company’s true competitive position, … More How can your growth strategy evolve faster than the market?
Customizing M&A diligence and integration priorities to a specific deal rationale promotes long-term growth. Companies often apply the same M&A diligence and integration playbooks to all deals, rather than tailoring activities to the strategic rationale behind the particular transaction. As more than half (52%) of companies expect to actively pursue M&A in the next 12 … More How you should align your acquisition approach with your growth strategy
Effectively managing third-party supplier and customer contract separation is a critical task for CFOs and supply-chain leaders. A typical divestiture includes hundreds or thousands of supplier and customer contracts that need to be correctly assigned to the company being divested (DivestCo). Whether a carve-out sale or tax-free spin, separating contracts may take up to 12 … More Five steps to manage contract separation during divestitures
An increasing number of companies are waiting to go public, and they will be ready to move quickly when markets recover. The backlog of high-quality IPOs continues to grow as issuers await more favorable market conditions, pushing IPO activity down across many markets in Q3 2019 compared with Q3 2018. Overall, 256 IPOs came to … More Global IPO trends: Q3 2019
When it comes to merger integration, convergence matters Leaders in the technology, media and entertainment, and telecommunications (TMT) sectors understand the challenge of creating long-term value from M&A, and likely are aware of a recent acquisition that failed to fully achieve pre-deal expectations. As the nature and purpose of TMT dealmaking evolves, corresponding changes to … More Merger integration in a converging world
The global medical technology (medtech) industry grew by 5% in 2016, a pace last seen before the financial crisis. This strong performance was fueled by mergers and acquisition (M&A) and portfolio optimization strategies, as well as continued focus on capital efficiency and research and design (R&D) investments, according to Pulse of the industry, the 2017 … More Global medtech revenue bounces back, though focus on sustainable growth must continue
Read the full press release here. Business confidence is high among European middle-market organizations, despite geopolitical uncertainty within and outside Europe, demographic shifts and rapid digitization across sectors according to the EY Growth Barometer: Europe. The study reveals that almost four in ten (38%) European middle-market companies are targeting current year growth of 6% to … More European middle-market organizations forecast their growth to outpace the eurozone over next 12 months
Global M&A activity among telecommunications (telco) companies reflects the ongoing transformation impacting the sector in response to increasing competitive intensity, evolving consumer behaviors and disruption from so-called “over-the-top” (OTT) players, which deliver audio, video or other media over the internet without the involvement of a multiple system operator in the control or distribution of the … More Data privacy considerations in telecommunications M&A: do you know your risk?
Read more on our Global Newsroom. The global mergers and acquisitions (M&A) market remained strong during the first half of 2017, despite rising protectionist sentiment and increasing intervention in deals by governments and regulators. The outlook for the remainder of the year and beyond is positive, particularly with private equity (PE) investors returning to the … More New deal terrain is no barrier for traditional players as global M&A activity remains strong
It was supposed to be a bad year for biotech. For this sector, the simplest of truisms has always held: what goes up must eventually come down. Markets peaked in 2015 and declined in 2016; payer pressure and US election year rhetoric weighed on the sector; drug approvals fell sharply; and biotech companies faced a … More Beyond borders: Biotechnology report 2017 – Staying the course